Loading...
  • participants
  • This will be a 2-panel, randomized ( participants are assigned different treatments based on chance), double-blind (neither investigator nor participant knows which treatment the participant receives), placebo-controlled (placebo is an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial), multicenter study. (clinicaltrials.gov)
  • This is an open-label (the researchers and participants know the treatment the participant is receiving) long-term extension study. (clinicaltrials.gov)
  • Participants will continue SSRI treatment with their prescribing physician, in conjunction with study participation. (clinicaltrials.gov)
  • This is a single arm trial in which all participants recieved open label aripiprazole augmentation of their current escitalopram, citalopram or sertraline treatment. (clinicaltrials.gov)
  • psychiatric
  • STOCKBRIDGE, Mass., Jan. 15 /PRNewswire-USNewswire/ -- In 1992, the Austen Riggs Center, a small, not-for-profit psychiatric hospital and residential treatment center in Western Massachusetts, began to follow 226 admitted patients in a multidimensional follow-along study that asked, among others, a most basic question: Can these patients recover? (bio-medicine.org)
  • An important consideration in understanding posttraumatic stress disorder (PTSD) is its frequent co-occurrence with other psychiatric disorders. (mental-health-matters.com)
  • psychotherapy
  • At the Personality Disorders Institute at Cornell's Weill Medical College, randomized controlled trials have shown that borderline patients make lasting improvements with a psychodynamic treatment called "transference focused psychotherapy. (bio-medicine.org)
  • What's all the more striking is that impressive outcomes in previously "treatment resistant" patients can be produced by a treatment method -- long-term psychodynamic psychotherapy -- that has for decades been dismissed as a mere historical curiosity. (bio-medicine.org)
  • severity
  • Adequate duration is often defined as a minimum of 6 weeks, stemming from the observation that fewer than 7% of patients who show little improvement following 6 weeks of treatment with fluoxetine eventually respond (ie, show a 50% decrease in symptom severity) following an additional 2 weeks of treatment. (psychiatrictimes.com)
  • After 4 weeks, intranasal esketamine treatment sessions will be individualized to either once weekly or once every other week at the fixed 2-week interval (based on clinical global impression - severity [CGI-S] performed at that visit), and every 4 weeks for subjects dosed at the 4 week interval. (clinicaltrials.gov)